Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
Avita Medical (RCEL) Stock Price & Analysis
313 Followers
RCEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.51 - $21.70
Previous Close$7.92
Volume206.98K
Average Volume (3M)261.94K
Market Cap
$204.33M
Enterprise Value$156.79M
Total Cash (Recent Filing)$89.06M
Total Debt (Recent Filing)$41.51M
Price to Earnings (P/E)-4.5
Beta2.20
Next Earnings
Aug 08, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding25,799,735
10 Day Avg. Volume295,083
30 Day Avg. Volume261,941
Standard Deviation0.20
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)4.63
Price to Sales (P/S)4.08
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.13
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda-4.79
Forecast
1Y Price Target
$23.75Price Target Upside187.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Avita Medical News
PremiumPress Releases
AVITA Medical to Host Investor Webinar Briefing
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityAVITA closed on a $90M debt financing facility with OrbiMed, providing financial flexibility with $50M available based on achieving certain revenue thresholds.
Product LaunchAVITA launched PermeaDerm in the U.S., marking the first step towards building a broad wound care franchise.
Regulatory MilestoneThe FDA's approval of RECELL for broader applications has significantly expanded the Company's market reach.
Bears Say
Financial GuidanceAVITA lowers its Q1 commercial revenue outlook to $11.0M-$11.3M from $14.8M-$15.6M, signaling potential concerns over the company's financial performance.
Management CredibilityThe first significant black eye for relatively new CEO Jim Corbett, indicating management's guidance was too aggressive, may shake investor confidence.
Regulatory ChallengesAVITA experienced a slower-than-expected start due to delays in securing approval for RECELL in trauma centers, which may hinder near-term revenue growth.
---
Ownership Overview
2.54% Insiders
9.62% Mutual Funds
15.95% Other Institutional Investors
71.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCEL FAQ
What was Avita Medical’s price range in the past 12 months?
Avita Medical lowest stock price was $7.51 and its highest was $21.70 in the past 12 months.
What is Avita Medical’s market cap?
Currently, no data Available
When is Avita Medical’s upcoming earnings report date?
Avita Medical’s upcoming earnings report date is Aug 08, 2024 which is in 83 days.
How were Avita Medical’s earnings last quarter?
Avita Medical released its earnings results on May 13, 2024. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.345 by -$0.385.
Is Avita Medical overvalued?
According to Wall Street analysts Avita Medical’s price is currently Undervalued.
Does Avita Medical pay dividends?
Avita Medical does not currently pay dividends.
What is Avita Medical’s EPS estimate?
Avita Medical’s EPS estimate is -$0.48.
How many shares outstanding does Avita Medical have?
Avita Medical has 25,799,734 shares outstanding.
What happened to Avita Medical’s price movement after its last earnings report?
Avita Medical reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.345. Following the earnings report the stock price went up 4.431%.
Which hedge fund is a major shareholder of Avita Medical?
Among the largest hedge funds holding Avita Medical’s share is Driehaus Capital Management LLC. It holds Avita Medical’s shares valued at 3M.
---
Avita Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.75 (187.18% Upside)
$23.75 (187.18% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 286.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $21.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.81%
12-Months-Change
Fundamentals
Return on Equity
-81.39%
Trailing 12-Months
Asset Growth
5.14%
Trailing 12-Months
Company Description
Avita Medical
Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.
---
RCEL Company Deck
---
RCEL Earnings Call
Q1 2024
0:00 / 0:00
---
RCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
---
RCEL Stock 12 Month Forecast
Average Price Target
$23.75
▲(187.18% Upside)
Technical Analysis
Best Analysts Covering RCEL
1 Year
1 Year Success Rate
3/17 ratings generated profit
1 Year Average Return
-27.28%
reiterated a buy rating 4 days ago
Copying Brooks O'Neil's trades and holding each position for 1 Year would result in 17.65% of your transactions generating a profit, with an average return of -27.28% per trade.
---